The companies have entered into a 3yr. agreement to manufacture AstraZeneca’s COVID-19 vaccines in the future. The recent agreement is an extension of the 2020 master supply & development agreement
AstraZeneca will have access to Oxford Biomedica’s Oxbox manufacturing facility to produce its vaccine on an as-needed basis beyond 2022 which is expected to complete in Q4’22. Oxford anticipates total revenues of ~$36.2M from AstraZeneca in the present financial year under the terms of the original agreement
Under the Sept 2020 agreement, Oxford received $18.1M up front as a capacity reservation fee & an additional revenue over $36.58M along with materials costs for the manufacture of multiple large-scale batches of AZD1222
Ref: Oxford Biomedica | Image: Astrazeneca
